We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From May 2019 to May 2024
By Maria Armental
Swiss drug giant Novartis AG is launching a generic version to Mylan NV's EpiPen, the emergency treatment for allergic reactions that's been beleaguered by pricing and supply challenges.
Novartis's Sandoz generic-drug unit had bought the U.S. commercial rights for the emergency shot, Symjepi, from Adamis Pharmaceuticals Corp. Symjepi, a small device that fits into the palm of a hand, contains the same active ingredient as EpiPen, epinephrine, though it's not an exact copy of EpiPen.
It will be available to institutional customers before it's sold to the public, Sandoz said, and will be first marketed as a 0.3 mg injection for patients who weigh at least 66 pounds and are determined to be at a higher risk for anaphylaxis.
The companies are working to launch a 0.15 mg injection to treat patients who weigh 33 to 65 pounds.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
January 16, 2019 17:13 ET (22:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
